Impact Biomedical Inc. (IBO) Stock Price & Analysis
Impact Biomedical Inc. (IBO) fell 7.41% to USD 0.5 as of September 9, 2026 at 10:43 UTC, according to Nexqual real-time market data.
IBO last closed at USD 0.54; the session ranged USD 0.5–0.53 on volume of 147,505 shares. Market capitalization is $53.91M, with a 52-week range of USD 0.37–0.83 (ASE). Source: Nexqual, September 9, 2026 at 10:43 UTC.
Key Statistics (as of September 9, 2026 at 10:43 UTC)
| Price | USD 0.5 |
|---|---|
| Change | ▼ 7.41% (down) |
| Previous Close | USD 0.54 |
| Open | USD 0.51 |
| Day Range | USD 0.5 – 0.53 |
| 52-Week Range | USD 0.37 – 0.83 |
| Volume | 147,505 shares |
| Market Cap | $53.91M |
| Exchange | ASE |
Technical Analysis (IBO)
Nexqual's technical model rates IBO "STRONG BUY" based on 5 bullish and 0 bearish signals across 127 daily candles, as of September 9, 2026 at 10:43 UTC.
| Overall Signal | STRONG BUY |
|---|---|
| RSI (14) | 58.43 (neutral) |
| vs SMA50 | Above (USD 0.45) |
| MACD | 0.01 (positive) |
Analyst Ratings (IBO)
Wall Street analysts rate IBO "None", per Nexqual as of September 9, 2026 at 10:43 UTC.
| Consensus Rating | None |
|---|
Earnings (IBO)
Source: Nexqual, September 9, 2026 at 10:43 UTC.
Financials & Fundamentals (IBO)
| Total Revenue | $35,000 |
|---|---|
| Revenue Growth (YoY) | -57.10% |
| Gross Margin | +0.00% |
| Operating Margin | -23400.00% |
| Profit Margin | +2260.00% |
| ROE | +23.46% |
| Debt / Equity | 9.49 |
| Current Ratio | 0.16 |
| Total Cash | $10,000 |
| Total Debt | $0 |
| Free Cash Flow | $1.02M |
Source: Nexqual, September 9, 2026 at 10:43 UTC.
Financial Health Score (IBO)
Nexqual rates Impact Biomedical Inc.'s overall financial health "Mixed" across five dimensions, as of September 9, 2026 at 10:43 UTC.
| Growth | Critical — Revenue -57% YoY (latest Q), sharp decline |
|---|---|
| Profitability | Critical — Heavily loss-making — early-stage company |
| Balance Sheet | Solid — $10K cash, no debt |
| Cash Flow | Strong — FCF $1M, 2905% margin |
| Efficiency | Strong — ROE 23%, ROA -17.8% |
Ownership (IBO)
| Insider Ownership | +89.02% |
|---|---|
| Institutional Ownership | +3.56% |
| Shares Outstanding | 107.82M |
| Float | 11.49M |
| Short % of Float | +4.65% |
Source: Nexqual, September 9, 2026 at 10:43 UTC.
Leadership (IBO)
Impact Biomedical Inc. is led by Frank D. Heuszel Esq. (age 68), Chairman & CEO, per Nexqual as of September 9, 2026 at 10:43 UTC.
| Chairman & CEO | Frank D. Heuszel Esq. (age 68) |
|---|---|
| CFO, Secretary & Treasurer | Todd D. Macko (age 52) |
| Chief Operating Officer | Mark J. Suseck (age 63) |
Major Backers & Investors (IBO)
Notable institutional backers of Impact Biomedical Inc. include Fidelity, according to Nexqual as of September 9, 2026 at 10:43 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Fidelity | 0.88% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 2.06% |
| Geode Capital | 1.1% |
| State Street | 0.56% |
| BlackRock | 0.24% |
| Northern Trust | 0.22% |
Source: Nexqual, September 9, 2026 at 10:43 UTC.
From Impact Biomedical Inc.'s Latest SEC 10-K Filing (filed 2026-03-11)
Key Strengths & Strategy (as disclosed to the SEC)
- Chemia is a leading developer and manufacturer of fragrances and flavors.   In addition to Chemia, IBO is actively seeking potential partners for further development and commercialization of 3F worldwide, given the broad application of this technology.   Composition patents have been issued in the U.S. and are pending in other countries.   Equivir   Equivir/Equivir G technology is a novel blend of FDA Generally Recognized as Safe (GRAS) eligible polyphenols (e.g.
- In order to protect our proprietary technology and processes, we also rely in part on confidentiality and intellectual property assignment agreements with our corporate partners, employees, consultants, outside scientific collaborators and sponsored researchers and other advisors.
- The protective steps we have taken may be inadequate to deter our competitors from using our proprietary information.
- Despite our efforts to protect our proprietary rights, unauthorized parties may copy aspects of our services or technology, obtain and use information, marks, or technology that we regard as proprietary, or otherwise violate or infringe our intellectual property rights.
Partnerships
- However, this risk would be mitigated in the event the Company is successful entering into a co-development agreement with a pharma partner for late stage clinical development.
- In addition, our licensors may terminate their agreements with us in the event we breach the applicable license agreement and fail to cure the breach within a specified period of time.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| XHLD | TEN Holdings, Inc. | USD 9.38 | ▲ 1.63% |
| PLRZ | Polyrizon Ltd. | USD 11.15 | ▼ 11.23% |
| OSRH | OSR Health, Inc. | USD 0.2 | ▼ 17.55% |
| KIDZ | KIDZ AI Inc. | USD 3.69 | ▼ 7.75% |
| TNON | Tenon Medical, Inc. | USD 3.36 | ▼ 10.88% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: September 9, 2026 at 10:43 UTC. This page is informational and not investment advice.